Skip to main content
NewslettersWatchlist

Fusion Pharmaceuticals Inc(FUSN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low21.43
Day High21.51
Open:21.50
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

AstraZeneca buys Hamilton-based smart cancer drug maker Fusion Pharmaceuticals for $2-billion

Deal will be ‘good for Canada’ as buyer will keep and expand local manufacturing presence, former Fusion chairman says
Newswire.ca
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Newswire.ca
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
Barchart
Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock
Newswire.ca
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
The Globe and Mail
Wednesday’s analyst upgrades and downgrades
Barchart
Stocks Recover on Lower Bond Yields and Strength in Energy Stocks
Barchart
Stocks Rise in Afternoon Trade
Barchart
Weakness in Chip Stocks Leads the Broader Market Lower
The Globe and Mail
Tuesday’s analyst upgrades and downgrades
Barchart
S&P Slips Ahead of FOMC Meeting, U.S. Housing Data in Focus
Newswire.ca
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Newswire.ca
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Newswire.ca
Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting
Newswire.ca
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences
Newswire.ca
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy
Newswire.ca
Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Newswire.ca
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart
S&P Futures Tick Lower as Key U.S. Jobs Report Looms
Newswire.ca
Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates
The Globe and Mail
Wednesday’s analyst upgrades and downgrades
Newswire.ca
Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration
Newswire.ca
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Profile

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing radiopharmaceuticals as precision medicines. The compnay's lead program includes FPI-1434, which is in clinical trial. Fusion Pharmaceuticals Inc. is based in Hamilton, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.